The impact of oral squamous cell carcinoma (OSCC) diagnosis and treatment on sexual behavior and relationship stress with respect to HPV status was evaluated in this study. Participants included patients with HPV-positive and HPV-negative disease, as well as partners.
Patients with oropharyngeal tumors that harbor HPV16 have higher 5-year survival and lower recurrence rates than patients with tumors that harbor other HPV strains or are HPV-negative.
Transoral robotic surgery (TORS) with or without radiation therapy or chemotherapy is an effective treatment option for patients with oropharyngeal cancer regardless of their p16 status.
Despite a higher risk for HPV-negative orophayngeal squamous cell carcinoma (OPSCC), poor oral health appears to be associated with OPSCC regardless of HPV status.
The incidence of oropharyngeal squamous cell carcinoma is increasing among older patients residing in the United States, likely due to the increase in HPV-associated malignancies.
Cervical cancer, and oropharyngeal cancers in men, account for most HPV-associated cancers.
Although HPV vaccination is expected to decrease the cancer burden from HPV across all racial and ethnic groups, some disparities are expected to persist and widen if their causes are not addressed, including lack of access to screening, timely diagnoses, and treatment.
Staging by Lymph Node Categories Shown to Better Predict Survival in Patients With Oropharyngeal CancerMarch 15, 2016
The current staging system for oropharyngeal cancer does not adequately differentiate HPV-positive from HPV-negative OPC. These researchers suggest regional OPC lymph node (N) categories and nasopharyngeal N categories might be more useful in staging HPV-positive OPC.
Posttreatment imaging at 3 months and physical examinations during the 6 months following treatment can detect most recurrences in patients treated with definitive radiation therapy for HPV-associated oropharyngeal cancer.
Among patients treated for oropharyngeal cancers linked to human papillomavirus (HPV) infection, at least 1 HPV-infection antibody could help identify those patients at risk for a recurrence of the cancer.
HPV-positive oropharyngeal cancer prevalence varies between Western Europe and Eastern Europe, according to study data.
Depression is a significant predictor of 5-year survival and recurrence in patients with head and neck cancer. These findings represent one of the largest studies to report on the impact of depression on cancer survival.
Oropharyngeal cancer patients with detectable traces of human papillomavirus type 16 (HPV16) in their saliva after cancer treatment are at an increased risk for recurrence.
Patients with oropharyngeal cancer who were found to have detectable traces of human papillomavirus type 16 (HPV16) in their saliva.
The presence of certain human papillomavirus (HPV)-16 antibodies in the blood is associated with improved survival rates for patients with HPV-related oropharyngeal carcinoma.
Detection of human papillomavirus (HPV)16 DNA in oral rinses following treatment for HPV-positive oropharyngeal carcinoma could be a potential tool for long-term tumor surveillance, a study concluded at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.
Human papillomavirus (HPV) vaccine may be a cost-effective approach for preventing squamous cell oropharyngeal cancer.
Mixed views have been expressed in relation to explaining the causal role of HPV in oropharyngeal cancer.
Human papillomavirus (HPV)-positive oropharyngeal cancer may not require neck surgery after receiving radiation therapy and chemo.
Physicians have developed blood and saliva tests that help accurately predict recurrences of HPV-linked oral cancers in a substantial number of patients. The tests screen for DNA fragments of the HPV shed from cancer cells lingering in the mouth or other parts of the body.
Human papillomavirus (HPV) positivity is associated with improved survival after disease progression, according to a study.
Reduced-dose intensity-modulated radiotherapy after complete clinical responses to induction chemotherapy for operable stage III/IVA, human papillomavirus (HPV)-positive head and neck cancer appears to be safe and might improve patients' quality of life.
ANAHEIM, CALIFORNIA—Among oropharyngeal patients receiving radiotherapy, gabapentin improved pain management and reduced weight loss, which potentially prevents the need for placement of a gastrostomy tube, according to a study presented at the Oncology Nursing Society (ONS) 39th Annual Congress.
Most oropharyngeal cancers in the United States diagnosed between 1995 and 2005 were positive for human papillomavirus (HPV), according to a study.
Initial symptom presentation seems to differ for human papillomavirus (HPV)-positive versus HPV-negative patients with oropharyngeal squamous cell carcinoma, according to a study.
Oropharyngeal cancer patients treated with combined chemotherapy and radiation therapy reported a decrease in their voice and speech quality for up to a year after the completion of treatment.
People with late-stage cancer at the back of the mouth or throat that recurs after chemotherapy and radiation treatment are twice as likely to be alive 2 years later if their cancer is caused by the human papillomavirus.
Increased incidence of of oropharyngeal squamous cell carcinoma (OPSCC) among patients younger than 45 years seen, and steady increase in proportion of grade III/IV tumors.
The human papillomavirus (HPV) may be to blame for the alarming increase of young adults with oropharyngeal cancer.
Survival highest for patients with both surgery, radiation, but lowest in African-Americans.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- National Health Care Spending Expected to Grow Five Percent Annually
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- 1 Year of Adjuvant Trastuzumab Improves Long-Term DFS in Early Breast Cancer
- Lenalidomide Maintenance Appears Efficacious for Relapsed DLBCL
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|